Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CECR2 is a bromodomain-containing protein that functions as a regulator within ATP-dependent chromatin remodeling complexes, especially the CERF-1 and CERF-5 ISWI complexes, which facilitate DNA access for replication, transcription, and repair. CECR2 binds acetylated and butyrylated lysine residues on histones, thus acting as a histone acetyl-lysine reader. It is essential for neurulation during embryogenesis, inner ear development, and spermatogenesis. Mutations or deletions in CECR2 are linked to Cat Eye Syndrome and have been associated with neurodevelopmental disorders including ASD. The protein also plays a role in DNA repair and apoptosis.
Drugs targeting CECR2 would be expected to inhibit or modulate its bromodomain–histone acetyl-lysine binding activity, thereby affecting chromatin remodeling and gene expression (no approved drugs currently)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chromatin remodeling regulator CECR2 (CECR2).